Mobile App

Google Play Apple Store

Independent Conference Coverage from The International Liver Congress™ (ILC)* 2017
Certified CME/CNE Activity - Research Roundup
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.
Review Research Roundup newsletter. Claim 1.0 AMA or ANCC credit/contact hour(s) after completion of each brief Post-Test/Evaluation.
Kris V. Kowdley
Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
Director, Liver Care Network
Swedish Medical Center
Clinical Professor of Medicine
University of Washington

Independent Conference Coverage from The International Liver Congress™ (ILC)* 2017
Certified CME/CNE Activity - Research Roundup

Kris V. Kowdley
Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
Director, Liver Care Network
Swedish Medical Center
Clinical Professor of Medicine
University of Washington
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.
Review Research Roundup newsletter. Claim 1.0 AMA or ANCC credit/contact hour(s) after completion of each brief Post-Test/Evaluation.
Kris V. Kowdley
Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
Director, Liver Care Network
Swedish Medical Center
Clinical Professor of Medicine
University of Washington



 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.


Overview

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Independent Conference Coverage from The International Liver Congress™ (ILC)* 2017

Certified CME/CNE Activity - Research Roundup

Kris V. Kowdley
Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
Director, Liver Care Network
Swedish Medical Center
Clinical Professor of Medicine
University of Washington
*This conference coverage is not sanctioned by the conference organizers (European Association for the Study of the Liver) and is not an official part of the conference proceedings from ILC 2017.

20
Supported by an independent educational grant from
Gilead Sciences Medical Affairs
1300
Expired Activity
Mini Module
6143
../../../PR_Files/PrintArticles/Images/Nash_2017/Banner_Nash_2017_2.gif
  • Liver Disease
  • Archives
Liver Disease
Change Settings